Ascendant Diagnostics | Tear-Based Breast Cancer Diagnosis
Ascendant Dx is an early stage biotechnology company that was formed in September of 2010 with a focus on developing innovative new approaches to improve the diagnosis of serious disease and conditions.
Ascendant’s first product in development is an in vitro diagnostic assay to detect early stage breast cancer utilizing the proteomic profile present in tears. Implementation of our test in the market place will lead to greater rates of survivability by increasing early detection of breast cancer.
We believe our simple, non-invasive tear-based collection method will rapidly lead to increased participation by individuals who choose not to utilize currently available yearly screening methods.
- Life Sciences
- 535 W. Research Center Blvd.
- Fayetteville, AR 72701
- Omid Moghadam,
- Chief Executive Officer
- Anna Daily, PhD
- Senior Scientist
- Kimberley Fuller,
- Director of Market Research
- and Business Development
Water treatment startup BlueInGreen of Fayetteville is expanding its North American sales presence with partnerships that will help make its products more readily available in Atlantic Canada, Texas and Virginia.
Acxiom Corp. of Little Rock said Thursday that it has expanded its partnership with global microblogging giant Twitter Inc. of San Francisco.
Startup Junkie of Fayetteville will host the SBA's InnovateHER competition on March 27. It will feature innovate products and services that can help empower women's lives.
Noro-Moseley is a venture-capital fund that has been increasing its activity in Arkansas. In 2010, it invested $3.5 million in Fayetteville's Acumen Brands.